
News|Podcasts|May 12, 2025
Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management
Author(s)Alexandra Gerlach, Associate Editor
Explore the latest insights on emerging antibody drug conjugates for HER2 breast cancer and real-world management strategies.
Advertisement
In this episode of the Pharmacy Times Peer Exchange feature series about antibody drug conjugates (ADCs) and human epidermal growth factor receptor 2 (HER2) breast cancer (BC), oncology pharmacists discuss novel, emerging ADCs and real-world management of these therapies.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nerandomilast Receives FDA Approval for Idiopathic Pulmonary Fibrosis
2
Study Shows Infliximab Biosimilar is Safe in Patients Undergoing RA Treatment
3
Dexamethasone-Sparing Regimen Offers Safer Option for Frail Patients With MM
4
Pneumococcal Polysaccharide Vaccination Does Not Reduce Rates of Cardiovascular Events
5